Yinuo Pharmaceuticals is a small molecule inhibitor drug developer. The company focuses on the development of the world’s first small molecule inhibitor drugs targeting the innate immune system. Based on 26 years of original research, it has developed the world’s first small molecule MyD88 inhibitor, which can be used to treat a wide range of severe major immune disorders. Recently, Yinuo Pharmaceuticals completed the Pre-A round of financing of 40 million yuan. This round was led by Zhuhai Huajin Capital, a subsidiary of Zhuhai Huafa Group, followed by Beijing Zhongbojuli and Zhuhai Hi-Tech Venture Capital.
This article is transferred from: https://www.itjuzi.com/investevent/13796604
This site is only for collection, and the copyright belongs to the original author.